guadecitabine: Clinical Trials

32 trials of guadecitabine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 7 active not recruiting, 3 terminated, 3 unknown. 20 Phase 2, 15 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 220Completed 10, Active not recruiting 4, Terminated 3, Unknown 2, Withdrawn 1
Phase 115Completed 7, Active not recruiting 5, Terminated 1, Unknown 1, Withdrawn 1
Phase 33Completed 3

Follow guadecitabine: new trials by email Literature Review of guadecitabine trials Research Report on guadecitabine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Belinostat, Biopsy Procedure, Biospecimen Collection - Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma
Phase 2Active not recruitingNational Cancer Institute (NCI)192020-09-082026-11-13
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
Ipilimumab plus nivolumab plus guadecitabine, Ipilimumab plus nivolumab - Melanoma, Non Small Cell Lung Cancer
Phase 2UnknownItalian Network for Tumor Biotherapy Foundation1842020-03-012020-01-31
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Guadecitabine, Nivolumab - Colorectal Adenocarcinoma, CpG Island Methylator Phenotype
Phase 1 / Phase 2WithdrawnUniversity of Southern California2020-01-302021-04-05
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
Guadecitabine, Carboplatin - Small Cell Lung Cancer, Extensive-stage Small Cell Lung Cancer
Phase 2CompletedShadia Jalal, MD242019-06-062023-12-20
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
Guadecitabine - Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 2UnknownGroupe Francophone des Myelodysplasies402018-11-012018-11-15
Guadecitabine Extension Study
Guadecitabine - Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome
Phase 2TerminatedAstex Pharmaceuticals, Inc.352018-07-182024-08-27
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Durvalumab, Guadecitabine - Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type
Phase 1Active not recruitingUniversity of Southern California552018-02-072026-06-01
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Guadecitabine, Durvalumab - Advanced Kidney Cancer, Kidney Cancer
Phase 1 / Phase 2Active not recruitingAjjai Alva, MD572017-12-192022-02-17
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
Durvalumab, Tremelimumab, SGI-110 - Extensive-stage Small Cell Lung Cancer
Phase 1CompletedCatherine Shu22017-12-152018-12-10
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Atezolizumab, Guadecitabine - Urothelial Carcinoma
Phase 2Active not recruitingFox Chase Cancer Center212017-11-272021-11-04
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)92017-11-082026-10-20
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
SGI-110 (guadecitabine) - Paraganglioma, Gastrointestinal Stromal Tumors
Phase 2TerminatedNational Cancer Institute (NCI)92017-08-162026-02-18
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Pembrolizumab, Guadecitabine, Mocetinostat - Lung Cancer
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center282017-08-042026-08-05
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
guadecitabine, Treatment Choice (TC) - Acute Myeloid Leukemia
Phase 3CompletedAstex Pharmaceuticals, Inc.3022017-03-162024-08-28
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
Guadecitabine, Pembrolizumab, ASTX727 - Non Small Cell Lung Cancer
Phase 1Active not recruitingRoyal Marsden NHS Foundation Trust602017-01-262026-05-12
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Guadecitabine, Treatment Choice - Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Phase 3CompletedAstex Pharmaceuticals, Inc.4172017-01-132024-08-27
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Guadecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Phase 2CompletedNorthwestern University452016-11-112024-02-20
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Atezolizumab, Guadecitabine - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Phase 1 / Phase 2Active not recruitingUniversity of Southern California332016-11-022026-07-07
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Atezolizumab, Guadecitabine - Acute Myeloid Leukemia
Phase 1CompletedHoffmann-La Roche402016-10-312020-03-13
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
Donor Lymphocytes, Guadecitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2CompletedM.D. Anderson Cancer Center552016-06-222025-11-06

Showing 20 of 32. Sign in to see all of them.

Conditions studied

Leukemia, Myeloid, Acute (7)  ·  Myelodysplastic Syndromes (4)  ·  Leukemia, Myelomonocytic, Chronic (3)  ·  Ovarian Neoplasms (3)  ·  Carcinoma, Hepatocellular (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Colorectal Neoplasms (2)  ·  Fallopian Tube Neoplasms (2)  ·  Kidney Neoplasms (2)  ·  Melanoma (2)  ·  Small Cell Lung Carcinoma (2)  ·  Carcinoma, Transitional Cell (1)  ·  Cholangiocarcinoma (1)  ·  Colonic Diseases (1)

Sponsors

Astex Pharmaceuticals, Inc. (7)  ·  M.D. Anderson Cancer Center (3)  ·  National Cancer Institute (NCI) (3)  ·  University of Southern California (3)  ·  Italian Network for Tumor Biotherapy Foundation (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)  ·  Ajjai Alva, MD (1)  ·  Catherine Shu (1)  ·  Fox Chase Cancer Center (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  Hoffmann-La Roche (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Nasser Hanna (1)  ·  Northwestern University (1)  ·  Otsuka Pharmaceutical Co., Ltd. (1)

Countries

United States (27)  ·  Canada (7)  ·  Italy (6)  ·  United Kingdom (6)  ·  Japan (5)  ·  Denmark (4)  ·  France (4)  ·  South Korea (4)  ·  Spain (4)  ·  Belgium (3)  ·  Germany (3)  ·  Poland (3)  ·  Sweden (3)  ·  Austria (2)  ·  Czechia (2)

Top investigators

Ajjai Alva, M.D. (1)  ·  Anna Maria Di Giacomo, MD (1)  ·  Anna Maria Di Giacomo, PhD,MD (1)  ·  Anthony El-Khoueiry, MD (1)  ·  Betul Oran, MD (1)  ·  Casey O'Connell (1)  ·  Catherine Shu, MD (1)  ·  Daniela Matei, MD (1)  ·  Guillermo Garcia-Manero (1)  ·  Hagop M Kantarjian (1)  ·  Harold N Keer, MD, PhD (1)  ·  Heinz-Josef Lenz, MD (1)  ·  John W Glod, M.D. (1)  ·  Junji Ikeda (1)

Results publications

PMID 16882708, PMID 26296954, PMID 28445481, PMID 31060979, PMID 31331399, PMID 31831561, PMID 33289590, PMID 33531075, PMID 34552007, PMID 35671108, PMID 35717027, PMID 36302175, PMID 36934257, PMID 37276510, PMID 37739939, PMID 38231126, PMID 38302476, PMID 38312102, PMID 40454402

NIH funding

P30CA014089 (3), 2015 (1), P30CA016056 (1), P30CA060553 (1), UM1CA186686 (1)